Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 3/20 | 0.46 |
| ▸ | OXTR | P30559 | 2/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089575 | 0.88 | AVPR2 (0.49) | AVPR2OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL4863033 | 0.86 | AVPR2 (0.48) | AVPR2OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL4863777 | 0.84 | KMT2A (0.55) | AVPR2MEN1KMT2ALMNATP53 | |
| SCHEMBL4868271 | 0.83 | KMT2A (0.52) | AVPR2MEN1KMT2ALMNATP53 | |
| SCHEMBL4865179 | 0.81 | GFER (0.53) | AVPR2MEN1KMT2ALMNATP53 | |
| SCHEMBL4865660 | 0.81 | TP53 (0.49) | AVPR2OXTRAVPR1ALMNATP53 | |
| SCHEMBL4870861 | 0.80 | AVPR2 (0.49) | AVPR2OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL4863318 | 0.80 | AVPR2 (0.58) | AVPR2OXTRAVPR1ALMNATP53 | |
| SCHEMBL4869903 | 0.80 | AVPR2 (0.58) | AVPR2OXTRAVPR1ALMNATP53 | |
| SCHEMBL4869809 | 0.79 | AVPR2 (0.58) | AVPR2OXTRAVPR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | AVPR2 124/4885OXTR 96/4885AVPR1A 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.